JP2024530344A - 加齢黄斑変性の処置のためのｂ因子阻害剤の使用 - Google Patents

加齢黄斑変性の処置のためのｂ因子阻害剤の使用 Download PDF

Info

Publication number
JP2024530344A
JP2024530344A JP2024514000A JP2024514000A JP2024530344A JP 2024530344 A JP2024530344 A JP 2024530344A JP 2024514000 A JP2024514000 A JP 2024514000A JP 2024514000 A JP2024514000 A JP 2024514000A JP 2024530344 A JP2024530344 A JP 2024530344A
Authority
JP
Japan
Prior art keywords
iptacopan
administration
administered
eye
reduces
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024514000A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024530344A5 (enExample
Inventor
アルメル オリビア チャリル，アルノー
サンダー，オリバー
ザカリア，ナディア
Original Assignee
ノバルティス アーゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノバルティス アーゲー filed Critical ノバルティス アーゲー
Publication of JP2024530344A publication Critical patent/JP2024530344A/ja
Publication of JP2024530344A5 publication Critical patent/JP2024530344A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2024514000A 2021-09-07 2022-09-02 加齢黄斑変性の処置のためのｂ因子阻害剤の使用 Pending JP2024530344A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163241169P 2021-09-07 2021-09-07
US63/241,169 2021-09-07
PCT/IB2022/058275 WO2023037218A1 (en) 2021-09-07 2022-09-02 Use of factor b inhibitors for the treatment of age-related macular degeneration

Publications (2)

Publication Number Publication Date
JP2024530344A true JP2024530344A (ja) 2024-08-16
JP2024530344A5 JP2024530344A5 (enExample) 2025-09-10

Family

ID=83457168

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024514000A Pending JP2024530344A (ja) 2021-09-07 2022-09-02 加齢黄斑変性の処置のためのｂ因子阻害剤の使用

Country Status (5)

Country Link
US (1) US20240398779A1 (enExample)
EP (1) EP4398906A1 (enExample)
JP (1) JP2024530344A (enExample)
CN (1) CN117915915A (enExample)
WO (1) WO2023037218A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20250161347A1 (en) 2023-11-22 2025-05-22 Flagship Pioneering Innovations Vii, Llc Methods and compositions for treating non-alcoholic fatty liver disease

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3425B1 (ar) 2013-07-15 2019-10-20 Novartis Ag مشتقات البابيريدينيل-اندول واستخدامها كعامل متمم لمثبطات b

Also Published As

Publication number Publication date
EP4398906A1 (en) 2024-07-17
WO2023037218A1 (en) 2023-03-16
US20240398779A1 (en) 2024-12-05
CN117915915A (zh) 2024-04-19

Similar Documents

Publication Publication Date Title
Müskens et al. Systemic antihypertensive medication and incident open-angle glaucoma
US20220211691A1 (en) Treatment of dry eye disease
BR112020010659A2 (pt) uso de um antagonista do vegf para tratar disfunções oftalmológicas angiogênicas
Apushkin et al. Monitoring cystoid macular edema by optical coherence tomography in patients with retinitis pigmentosa
TW202128183A (zh) 用於治療多種病症之方法及組成物
TW200911265A (en) Pharmaceutical compositions and methods of treating dry eye disorders
BR112012003730A2 (pt) terapia com acetato de glatirâmer de baixa frequência
KR20040100844A (ko) 눈에 국소적으로 사용하기 위한 브리모니딘과 티몰롤의조합물
UA115647C2 (uk) Застосування аналога тестостерону і агоніста 5-нт1а для лікування сексуальної дисфункції
US20250205346A1 (en) Anti-c5 agent for treatment of dry age-related macular degeneration (amd) or geographic atrophy secondary to dry amd
WO2021252647A1 (en) Methods of improving retina-associated disease outcome using ccr3-inhibitors
JP2019521160A (ja) Ｃ反応性タンパク質関連疾患の治療のための１−メチルニコチンアミド
US20240398779A1 (en) Use of factor b inhibitors for the treatment of age-related macular degeneration
WO2016172205A1 (en) Managing ebola viral infections
Nguyen et al. Intravenous bevacizumab causes regression of choroidal neovascularization secondary to diseases other than age-related macular degeneration
US20240252497A1 (en) Use of complement factor d inhibitor for treatment of geographic atrophy secondary to age-related macular degeneration
CN121712505A (zh) 使用因子b抑制剂的方法
Lim et al. Sustained-release intravitreal liquid drug delivery using triamcinolone acetonide for cystoid macular edema in retinal vein occlusion
Vainshtein et al. Necrotizing herpetic retinopathy: a case of delayed acute retinal necrosis presentation in a patient with uncontrolled diabetes mellitus and complications
US20250295648A1 (en) Method for treating l-dopa-induced dyskinesia, parkinson's disease, or parkinson's disease motor disability using befiradol
Doan et al. PS-C20-4: SGLT2i-A potential antihypertensive agent in hypertension patients with type 2 diabetes mellitus
JP2024518787A (ja) 全身型重症筋無力症の処置のための補体因子ｄ阻害剤の使用
WO2024086555A1 (en) Uses of anti-c3 antibodies
Konovalova et al. A case of acute posterior multifocal placoid pigment epitheliopathy: clinical analysis and differential diagnosis
WO2024054412A1 (en) Methods and compositions for treating amyotrophic lateral sclerosis

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250902

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250902